Ultragenyx adds sixth FDA-approved product as FAYUVI targets Sanfilippo syndrome

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has received full U.S. Food and Drug Administration approval for FAYUVI, or rebisufligene etisparvovec-hopf, creating the first approved treatment targeting the underlying cause of Sanfilippo syndrome type A and adding a second commercial gene therapy to the company’s portfolio. The one-time intravenous AAV9 treatment carries a U.S. list price of $3.95 million and is indicated for pediatric patients with neurologic manifestations of mucopolysaccharidosis type IIIA who retain preserved neurodevelopmental function. Commercial product is expected to reach qualified U.S. treatment centers within 30 to 60 days, while Ultragenyx Pharmaceutical Inc. also receives a valuable Priority Review Voucher following the approval. The timing is particularly important because RARE shares had collapsed 44% earlier in September after the Phase 3 Aspire study in Angelman syndrome failed, leaving FAYUVI as a major test of whether Ultragenyx Pharmaceutical Inc.’s expanding approved-product portfolio can offset clinical volatility elsewhere in the pipeline.

FAYUVI becomes the sixth FDA-approved product associated with Ultragenyx Pharmaceutical Inc. and its second approved gene therapy, following the August authorization of GENGLYCOS for glycogen storage disease type Ia. That progression materially changes the corporate profile of Ultragenyx Pharmaceutical Inc. because the company is moving beyond dependence on Crysvita royalties and established rare-disease products into repeated commercialization of internally developed gene therapies. FAYUVI will probably remain a relatively small franchise compared with blockbuster medicines because Sanfilippo syndrome type A is exceptionally rare, but the combination of a high one-time price, unmet need and an established rare-disease commercial infrastructure can still make the product financially meaningful.

How does FAYUVI target the underlying cause of Sanfilippo syndrome type A?

Sanfilippo syndrome type A is caused by pathogenic variants in the SGSH gene that result in deficiency of the lysosomal enzyme sulfamidase. Without adequate sulfamidase activity, heparan sulfate accumulates inside cells and tissues, contributing to progressive neurological deterioration that can affect cognition, speech, motor function, behavior and ultimately survival. Existing care has largely focused on symptoms and supportive treatment because physicians previously lacked an FDA-approved medicine capable of addressing the enzyme deficiency responsible for the disease.

FAYUVI uses an adeno-associated virus serotype 9 vector to deliver a functional copy of the SGSH gene following a single intravenous infusion. The objective is to allow cells to produce functional sulfamidase, reduce heparan-sulfate accumulation and slow or prevent further neurological damage while sufficient function remains to preserve. That last point explains why the FDA label specifically refers to pediatric patients with preserved neurodevelopmental function rather than every person with advanced Sanfilippo syndrome type A, since irreversible neuronal damage may limit the benefit possible once disease has progressed extensively.

The indication therefore creates a strong incentive for earlier diagnosis. A one-time disease-modifying therapy becomes substantially more valuable if children can be identified before major cognitive and functional decline rather than after years of progressive symptoms. For Ultragenyx Pharmaceutical Inc., commercialization will consequently depend on more than convincing treating physicians about FAYUVI itself. The company also needs diagnostic pathways, genetic testing, referral networks and qualified treatment centers capable of identifying and treating an ultra-rare population before the therapeutic window narrows.

What evidence convinced the FDA to grant full approval rather than accelerated approval?

The FDA based the approval on open-label, single-arm clinical evidence comparing treated children with untreated historical controls, supported by long-term biochemical and developmental assessments. Children treated during the period of preserved neurodevelopmental function maintained or improved cognitive performance compared with the expected progression of untreated patients, while biomarker evidence showed reductions in heparan-sulfate-related disease burden. The development program included several clinical studies, and the FDA approval letter references NCT02716246, NCT04360265 and NCT04088734.

Using historical controls introduces more uncertainty than a large randomized placebo-controlled trial because treated and untreated populations can differ in ways beyond the therapy itself. Ultra-rare and rapidly progressive pediatric disorders, however, can make traditional randomized programs difficult to conduct, particularly once a biological intervention shows substantial potential benefit. The FDA ultimately issued standard full approval, an important regulatory distinction because FAYUVI is not entering the market under an accelerated approval dependent on subsequent verification of a surrogate endpoint.

Safety remains central because a single-dose gene therapy creates risks that cannot simply be eliminated by stopping treatment after administration. The FDA identified adverse reactions including increased liver enzymes, nausea, vomiting, fever, appetite reduction, decreased blood-cell counts and increased amylase, while the prescribing information carries a warning regarding thrombotic microangiopathy. Patients receive corticosteroids starting before infusion and continuing for at least eight weeks, and long-term monitoring remains important because integrating vector sequences theoretically create a potential tumor risk.

Can a $3.95 million therapy make economic sense in such a small patient population?

Ultragenyx Pharmaceutical Inc. has set the U.S. wholesale acquisition cost at $3.95 million for a one-time treatment, placing FAYUVI among the world’s most expensive medicines by upfront list price. The company argues that the figure should be viewed against the lifetime medical and supportive-care burden associated with progressive Sanfilippo syndrome type A, which Ultragenyx Pharmaceutical Inc. estimates can approach approximately $8 million. Reuters reported analyst estimates suggesting global peak FAYUVI sales of roughly $200 million to $250 million, illustrating that the therapy can remain commercially meaningful without treating thousands of patients annually.

The headline price does not equal net revenue because insurers, government programs and other payers may negotiate discounts or require evidence that a child meets precise treatment criteria. Gene therapies also create unusual payer challenges because essentially the entire pharmaceutical cost is incurred at treatment even though the expected clinical benefit is intended to extend for years. Ultragenyx Pharmaceutical Inc.’s UltraCare support infrastructure should help coordinate access, but reimbursement speed will become one of the most important early launch indicators.

The economics are also different from those of a chronic medicine. Ultragenyx Pharmaceutical Inc. can generate several million dollars of gross revenue when one eligible patient is treated, but there is no recurring annual FAYUVI prescription from that same child. Sustained growth therefore depends on continuously identifying newly diagnosed patients across the available treatment population and eventually expanding geographic access.

How important is FAYUVI to Ultragenyx Pharmaceutical Inc.’s existing business?

Ultragenyx Pharmaceutical Inc. generated $214 million of second-quarter revenue, up from $167 million a year earlier. Crysvita remained the largest contributor at $156 million, followed by Dojolvi at $27 million, Evkeeza at $21 million and Mepsevii at $10 million. The company ended June with $436 million of cash, cash equivalents and marketable securities while reporting a $92 million quarterly net loss and using $97 million of cash in operating activities.

Management maintained 2026 total revenue guidance of $730 million to $760 million before incorporating potential contributions from the latest gene-therapy launches and has said Ultragenyx Pharmaceutical Inc. remains on a path toward profitability in 2027. FAYUVI and GENGLYCOS could help that trajectory by increasing the proportion of revenue derived from internally controlled commercial products, although launch expenses, manufacturing costs and the unpredictable timing of one-time gene-therapy treatments can create quarterly volatility.

The Priority Review Voucher adds another financial asset. Such vouchers can be used to shorten the review of a future qualifying application or potentially sold to another company, with historical transaction values often running into tens of millions of dollars. Ultragenyx Pharmaceutical Inc. has not yet established what it will do with the FAYUVI voucher, but it represents additional economic value beyond treatment sales.

Why did RARE shares rise 12.6% but remain far below early September levels?

Ultragenyx Pharmaceutical Inc. shares closed at $14.50 on September 17, up 12.58% after the FAYUVI approval, with trading volume above 12 million shares. The stock finished essentially unchanged at $14.51 on September 18, indicating that the initial approval rally largely held through the next completed trading session. The apparent strength needs context, however, because RARE had closed at $26.53 on September 2 before dropping 44.03% to $14.85 on September 3 after the company’s unrelated Angelman syndrome Phase 3 setback.

FAYUVI has therefore repaired only a fraction of the valuation lost earlier in September. That contrast explains why approval is strategically important without fully restoring investor confidence in Ultragenyx Pharmaceutical Inc.’s pipeline. The company now owns six approved products and two approved gene therapies, but public-market valuation still reflects the cost of failed late-stage development alongside the value of successful commercialization.

The next phase will be measured less by another FDA headline and more by patient identification, payer authorizations and actual FAYUVI treatment volumes. At $3.95 million per infusion, Ultragenyx Pharmaceutical Inc. does not need hundreds of quarterly patients for the product to become financially visible. It does, however, need to demonstrate that an exceptionally high-priced therapy can move through the U.S. reimbursement system efficiently enough to convert scientific success into durable commercial value.